Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gracell Biotechnologies Inc.

Gracell Biotechnologies Acquisition Completed
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Participate in Jefferies Healthcare Conference
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Tickers GRCL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.